Clinical Research Directory
Browse clinical research sites, groups, and studies.
Impact of Microglial Activation on Synaptic Density in Alzheimer's Disease
Sponsor: Centre Hospitalier St Anne
Summary
This study aims to analyse, in vivo, the interplay between microglial activation and tau pathology in Alzheimer's disease (AD) using \[18F\]-DPA-714 and \[18F\]-Ro948 tracers by Position Emission Tomography (PET), and their consequences on synaptic density using \[11C\]-UCB-J, a recent PET radioligand. By coupling advanced neuroimaging techniques in AD patients, while comparing them to controls, we will be able to study, for the first time in humans, the interaction between neuroinflammation, tau pathology, synaptic density, and their impact on AD progression. Joint analyses of peripheral immune biomarkers, carried out as a secondary objective, will further aim at defining peripheral correlates of this interplay. Overall, we aim to refine AD subgroup classification in order to improve and to refine the design of new therapeutic trials.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
90
Start Date
2023-10-18
Completion Date
2028-04-17
Last Updated
2024-06-13
Healthy Volunteers
Yes
Conditions
Interventions
[11C]-UCB-J
PET tracer binding to "SV2A" protein, used to study synaptic vesicle density.
[18F]-DPA-714
PET tracer binding to "TSPO" protein, used to study microglial activation.
[18F]-RO-948
PET tracer binding to "tau" protein, used to study the topography of tau deposition.
[11C]-PiB
PET tracer binding to Aβ40 and Aβ42 fibrils and insoluble plaques containing the aforementioned Aß peptides, used to study the topography of amyloid deposition.
Locations (3)
CHU de Lille
Lille, France
GHU Saint Anne Psychiatrie & Neurosciences
Paris, France
CHU de Rouen
Rouen, France